Johnson & Johnson vs Las Vegas Sands Corp. — how do they compare? Johnson & Johnson trades at $250.66 (market cap $598.96B), while Las Vegas Sands Corp. trades at $45.5 (market cap $30.36B). The key difference: Johnson & Johnson is far larger — about 19.7× Las Vegas Sands Corp.'s market cap, and Las Vegas Sands Corp. pays the higher dividend (2.4%). Which is the better fit depends on your goals.
| JNJ | LVS | |
|---|---|---|
Market Cap | $598.96B | $30.36B |
Volume | 6,156,228 | — |
Sector | Health | Consumer Cyclical |
52-Week High | $267.24 | $69.49 |
52-Week Low | $164.36 | $44.78 |
Enterprise Value | $631.90B | $42.75B |
Dividend Yield | 2.15% | 2.4% |
Trailing returns across standard periods
Latest headlines on both assets
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →